HD Medical Awarded FDA Clearance For HD Steth
14.7.2020 15:05:00 EEST | Business Wire | Press release
HD Medical, Inc. of Silicon Valley today announces that its flagship product, HD Steth, has received FDA clearance for all three product classification codes of DQD, DQC and DPS for Electronic Stethoscope, Phonocardiograph and Electrocardiograph combined into one device. HD Steth utilizes cutting-edge AI technology to enable clinicians to perform advanced cardiac evaluation at the point-of-care to save time and lives.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200714005235/en/
HD Steth and HD Steth App (Photo: Business Wire)
About HD Steth
HD Steth is an intelligent stethoscope that assists clinicians with capturing, recording, replaying and simultaneously visualizing heart sounds and ECG waveforms on a smart device to help detect multiple cardiac abnormalities. Patented visualization and noise cancellation technology gives HD Steth its edge. Subtle heart sounds are difficult or impossible to hear during auscultation. HD Steth delivers unsurpassed sound fidelity enhanced by visualization which allows clinicians to see the heart sounds providing instant cardiac insights.
Clinical Studies & International Sales Success
“The quality and intensity of heart sounds are phenomenal on HD Steth and it delivers the most impressive sound quality advancements in my last 40 years of stethoscope use,” said Dr. Ethiraj Raj, specializing in Cardiovascular Disease in Flint, Michigan. “The opportunity to amplify the sounds along with simultaneous visualization of heart sounds and ECG in real-time is unique. Physicians, teachers and medical students will greatly benefit from this revolutionary experience which will be a paradigm shift in cardiac auscultation. Congratulations to the HD Medical team for combining all these sensors that resulted in this exceptional instrument which will benefit the patient population as well as providers for years to come. It is truly a giant leap forward in technology.”
“HD Steth is the only stethoscope with four powerful microprocessors built into the device for advanced signal processing and intelligence, while still retaining the convenient form factor of a stethoscope,” said Shailendra Mahajan, board observer and managing director of Maxim Ventures, a major investor in HD Medical. “Components and sensors by Maxim Integrated Products, Inc. (NASDAQ: MXIM) enable low power consumption and better accuracy. The combination results in significant advantages over other products in the market.”
“Over the past year, HD Medical has been conducting multiple screening studies of over 50,000 children using HD Steth in India and has resulted in saving many lives. HD Medical has been selling internationally to medical professionals and institutions as well as domestically to veterinarians with great success. HD Medical can now market HD Steth in the U.S. and in other FDA-predicated global markets,” said Arvind Thiagarajan, founder & CEO of HD Medical. “The most intelligent stethoscope has been FDA cleared at this critically important time. During this challenging COVID-19 pandemic, HD Steth will significantly assist frontline health workers at the point-of-care detecting abnormal heart and lung sounds," he continues, welcoming the medical community to High-Fidelity Digital “HD” sound and instant visualization.
About HD Medical, Inc.
HD Medical, Inc. is a Silicon Valley-based innovator of digital health solutions for AI-enabled detection and management of cardiovascular disease (CVD). HD Steth has been awarded FDA clearance (K201299) for Product Classification Codes: DQD, DQC, DPS. The company delivers its intelligent cardiac care solutions and products globally to medical professionals and institutions as well as veterinarians through channel partners. For more information please visit www.hdmedicalgroup.com.
Note to editors: HD Steth and HD Medical are registered trademarks of HD Medical, Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200714005235/en/
Contact information
Kristi Furrer
HD Medical, Inc.
303.525.0924
kristi@hdmedicalgroup.com
info@hdmedicalgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NetApp Completes Acquisition of PEAK:AIO to Accelerate Zettabyte-scale AI Deployments2.11.2026 15:00:00 EET | Press release
NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced that it completed the acquisition of PEAK:AIO, a pioneer in next-generation metadata architecture and high-performance parallel file systems. With this acquisition, NetApp can leverage metadata services and parallel namespace innovations to power the fastest storage on the planet, NetApp Novus, to support zettabyte-scale file systems for the most demanding workloads of AI clouds and GPU-as-a-service providers. For the best AI infrastructure economics, organizations need to keep GPU resources continuously supplied with data without bottlenecks. The acquisition advances NetApp’s strategy for the next phase of AI infrastructure by bringing PEAK:AIO’s metadata and parallel file system expertise together with NetApp ONTAP, giving customers a path to AI-scale storage that combines high concurrency and massive namespace growth with the resilience, security, and operational simplicity enterprises already trust
HistoSonics Receives Regulatory Approval in Singapore, Advancing Expansion Across Asia-Pacific2.11.2026 15:00:00 EET | Press release
HistoSonics today announced that the company has received market authorization from Singapore’s Health Sciences Authority (HSA) for its Edison® Histotripsy System (under the device name HistoSonics Histotripsy System), marking another significant milestone in the company’s continued international expansion and creating new opportunities to advance access to histotripsy throughout the Asia-Pacific region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261102090757/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image-guided platform that uses the mechanical properties of focused ultrasound, known as histotripsy, to mechanically destroy and liquefy unwanted tissue and tumors. The technology offers a fundamentally new approach to tissue destruction without the need for invasive procedures, radiation, or thermal energy. The Edison System is currently authorized for the destruction of liver
Bentley Systems Announces Seequent’s Acquisition of Seismic Interpretation Software Company Eliis2.11.2026 15:00:00 EET | Press release
Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, today announced that Seequent, The Bentley Subsurface Company, has acquired seismic interpretation software company Eliis. The acquisition will enrich Seequent’s capabilities in geophysics with seismic data interpretation and further advance subsurface understanding to help solve complex global challenges. Eliis’ global team of more than 100 geoscientists, technical specialists, and researchers will join Seequent. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261029964674/en/ 3D view from PaleoScan showcasing recent advancements in seismic interpretation workflows that support prospect evaluation and exploration decision-making Founded in 2007 and with headquarters in Montpellier, France, Eliis develops advanced seismic interpretation software that helps geoscientists process and analyze seismic imaging data to build detailed model
NIQ Publishes 2026 ESG Progress Report, Highlighting Action Across Climate, People, Communities, and Responsible AI2.11.2026 13:45:00 EET | Press release
NIQ (NYSE: NIQ), a leading consumer intelligence company, today released its 2026 Environmental, Social and Governance (ESG) Progress Report, detailing the company’s progress on key ESG priorities throughout 2025. The report covers NIQ’s efforts across environmental responsibility, its people and communities, data integrity, and responsible AI. Key highlights from 2025 include: Strengthened its approach to climate risk and environmental measurement: NIQ conducted its first climate risk assessment aligned with Task Force on Climate-related Financial Disclosures (TCFD) recommendations, tracked Scope 1, 2 and 3 emissions under the GHG Protocol, and externally verified its carbon footprint. Invested in associate development, engagement and well-being: Internal mobility increased to 35%, up from 30%, while performance review completion reached 99% and the employee survey response rate reached 89%. NIQ also introduced three new leadership development tracks, while Employee Assistance Program
Agenus Announces Nature Medicine Publication of Multicenter UNICORN Phase 2 Trial Demonstrating Deep Responses with Neoadjuvant BOT+BAL in Resectable Colon Cancer2.11.2026 13:42:00 EET | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of results from the investigator-sponsored, multicenter Phase 2 UNICORN trial evaluating short-course preoperative, or neoadjuvant, botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, alone or in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody, in patients with resectable, locally advanced colon cancer. The manuscript, titled “Preoperative botensilimab with or without balstilimab for patients with resectable, locally advanced pMMR or dMMR colon cancer: the UNICORN trial by GONO,” was published in Nature Medicine and is available at DOI 10.1038/s41591-026-04710-1. The UNICORN trial enrolled 56 patients in four non-randomized cohorts of 14, evaluating BOT alone or BOT+BAL in mismatch repair proficient/microsatellite stable (pMMR/MSS) and mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) colon cancer. The study ass
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom